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enterolAbstract—The performance of transabdominal ultrasound (US) in chronic pancreatitis (CP) following the advances
in US technology made during recent decades has not been explored. Our aim in this prospective study was to eval-
uate the diagnostic accuracyofmodern abdominal US comparedwith theMayo score inCP.One hundred thirty-four
patients referred for suspected CP were included in the study. Fifty-four patients were assigned the diagnosis CP.
After inclusion, transabdominal US was performed. Ductal features (calculi, dilations and caliber variations, side-
branch dilations and hyper-echoic duct wall margins) and parenchymal features (calcifications, cysts, hyper-
echoic foci, stranding, lobulation and honeycombing) were recorded. Features were counted and scored according
to a weighting system defined at the international consensus meeting in Rosemont, Illinois (Rosemont score). Diag-
nostic performance indices (95% confidence interval) of USwere calculated: The unweighted count of features had a
sensitivity of 0.69 (0.54–0.80) and specificity of 0.97 (0.90–1). The Rosemont score had a sensitivity of 0.81 (0.69–0.91)
and specificity of 0.97 (0.90–1). Exocrine pancreatic failure was most pronounced in Rosemont groups I and II
(p, 0.001). We conclude that using both unweighted and weighted scores, the diagnostic accuracy of modern trans-
abdominal US is good. The extent of pancreatic changes detected by the method is correlated with exocrine pancre-
atic function. (E-mail: Trond.engjom@helse-bergen.no)  2016 TheAuthors. Published by Elsevier Inc. on behalf
of World Federation for Ultrasound in Medicine & Biology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
KeyWords:Chronic pancreatitis, Transabdominal Ultrasound, Mayo score, Diagnostic accuracy, Sensitivity, Spec-
ificity, Exocrine pancreatic function.INTRODUCTION
Modern guidelines and reviews on chronic pancreatitis
(CP) include transabdominal ultrasound (US) as a rele-
vant first-line imaging method in the evaluation of the
pancreas (Conwell et al. 2014; Drewes et al. 2015;
Erchinger et al. 2011; Forsmark 2013; Martinez et al.
2013; Mayerle et al. 2013). No prospective studies have
reported the diagnostic performance using the mostddress correspondence to: Trond Engjom, Haukeland University
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735recent US technology. Endoscopic US (EUS) with
characterization of ductal and parenchymal changes
with or without the aid of weighted scores like the
‘‘Rosemont score’’ (Catalano et al. 2009) is presently
the gold standard for sonographic imaging of the
pancreas in CP. The Rosemont score was established
through an international consensus meeting in Rosemont,
Illinois (April 13–14, 2007). The result of the conference
was agreement on definitions and weighting for five
parenchymal and five ductal features of CP. The diag-
nostic quality of EUS compared with other imaging mo-
dalities like computed tomography (CT) and magnetic
resonance imaging (MRI) is regarded as good (Catalano
et al. 1998; Kalmin et al. 2011; Luetmer et al. 1989;
Manfredi et al. 2000; Pungpapong et al. 2007;
Wiersema and Wiersema, 1995). The severity of
pathologic EUS changes correlates to histopathologic






(n 5 70) p
Age 59 (24–79)* 55 (16–79)
Sex, female/male 29/25y 33/37




Alcohol units/week 0 (0–1) 1 (0–3) ,0.05
736 Ultrasound in Medicine and Biology Volume 43, Number 4, 2017findings and extent of exocrine dysfunction (Albashir
et al. 2010; Catalano et al. 1998; Chong et al. 2007;
Kalmin et al. 2011; Luetmer et al. 1989; Manfredi et al.
2000; Pungpapong et al. 2007; Wiersema and
Wiersema, 1995). However, low inter-rater agreement,
especially for the minor EUS-detected features in the
Rosemont score, has been reported (Del et al. 2012;
Kalmin et al. 2011; Stevens et al. 2010). The invasive
character of the EUS examination and the long learning
curve for operators are drawbacks of the method.
Transabdominal US is limited by longer sound wave
distance to the pancreas compared with EUS. Bowel gas,
obesity and individual patient factors reduce the quality
of US images. Previous studies have explored the visual-
ization of morphologic changes in CP by transabdominal
US and reported varying diagnostic accuracy with a
sensitivity of 70% to 80% (Bolondi et al. 1989; Foley
et al. 1980; Gebel et al. 1985; Ikeda et al. 1994;
Martinez-Noguera and D’Onofrio 2007). One large
study reported sensitivities for US .85% for the
features calcifications, pancreatic duct dilations and
cysts, compared with CT (Ikeda et al. 1994). In recent de-
cades, there has been an overall advance in US technol-
ogy (Dimcevski et al. 2013; Whitsett 2009).
Re-evaluation using modern technology is warranted
(Conwell et al. 2014). The advances in software and
screen technology and the introduction of harmonic im-
aging reduce noise and improve image resolution in all
US systems. Modern US probes with dynamic fre-
quencies, better depth-focusing technology and better
high-frequency probes also add significantly to noise
reduction and improved resolution. Especially in the
characterization of calcifications, where the evaluation
of shadowing is highly significant, overall reduction of
random noise features is important. In the detection of
minor changes in pancreatic ducts and parenchyma, we
postulate that improved image resolution probably in-
creases the sensitivity of the method compared with
earlier studies.
In this prospective observational cohort study, our
aim was to evaluate the diagnostic accuracy of features
detected by a high-end transabdominal US scanner
compared with the CP diagnosis defined by a diagnostic
score combining clinical and imaging features, the
Mayo score (Layer et al. 1994). Furthermore, US findings
were evaluated according to criteria from the Rosemont
consensus to address possible improvements in diag-
nostic accuracy from a weighted score.HbA1c, % 5.8 (5.4–6.6) 5.5 (5.1–5.7) ,0.05
Fecal elastase, mg/g 151 (16–458) 376 (189–508) ,0.05
Duodenal bicarbonate,
mmol/L
71 (38–101) 109 (90–122) ,0.05
* Minimum–maximum.
y Median (interquartile range) unless otherwise stated. Age (min–
max).METHODS
Participants
One hundred forty-one eligible participants were re-
cruited among patients referred to our outpatient clinicwith suspected CP. Reasons for referral were presenting
symptoms or classic CP characteristics based on previous
diagnostic imaging. Patients who did not fulfill the proto-
col for an adequate Mayo score were not included. We
excluded patients for whom US visualization of the
pancreas was insufficient because of obesity, repeated
overlying bowel air or other factors. The final number
of patients was 124. Patient characteristics are summa-
rized in Table 1.Diagnostic standards
Relevant clinical data and imaging reports from
EUS (n5 74), pancreatic CT (n5 111) and/or pancreatic
MRI (n5 22) were retrieved from the medical records or
obtained as necessary for the clinical workup. All EUS
examinations were performed according to a modern
standard using the linear EG-3870 UTK or radial EG-
3670 URK scope from Pentax Medical (Pentax Europe,
Hamburg, Germany) by two experienced operators
whose focus is pancreatic EUS. CT and MRI scans
were performed according to standardized and similar
protocols at different hospital scanners as part of the
routine diagnostic workup. All CT protocols included
intravenous contrast.Mayo score
On the basis of clinical information, endocrine and
exocrine failure, and findings on CT, MRI and EUS, pa-
tients were diagnosed according to a modified Mayo
score (also named Layer score) (Erchinger et al. 2013;
Layer et al. 1994) (Table 2). Patients with a Mayo score
$4 were diagnosed with CP.Sonographic examination
After overnight fasting, patients were examined with
US while in the supine or right lateral position, with the
Table 2. Mayo score: Diagnostic score for chronic
pancreatitis modified from Layer et al. (1994) *
Pancreatic calcifications or typical histologic findings 4 points
Moderate or marked morphologic changes on
ultrasonography, computed tomography or EST
3 points
Definite morphologic changes on magnetic resonance
imaging
3 points
Reduced exocrine pancreatic function by EST or fecal
elastase 1 level
2 points
History of acute pancreatitis or upper abdominal pain 2 points
Diabetes mellitus or impaired glucose tolerance test 1 point
EST 5 endoscopic.
* The diagnosis requires 4 points.
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rior left subcostal position. Each examination was per-
formed by a single operator. The skilled operators (T.E.,
F.E., G.D., 5–25 y of experience in pancreas scanning)
knew the reason for referral, but were blinded to clinical
data and results from earlier examinations. A GE Logic
E9 scanner with a 1- to 5-MHz curvilinear probe was
used. Whenever possible with respect to image depth
and quality, the examination was supplemented by aFig. 1. Images revealing different ultrasound-detected features
large, shadowing calcifications in the head and body of the pan
calcification in the main pancreatic duct (left arrow), with dila
image revealing chronic dilation and caliber variations in t9-MHz linear probe (GE Medical Systems and Primary
Care Diagnostics, Milwaukee, WI, USA). The default
abdomen configuration of the scanner was used to acquire
the images (CRA Probe—frequency: 4.0 MHz [CRA
Probe] and 9.0 MHz [linear probe], frame rate: 15–22 f/s,
dynamic range: 34, varying depth of scanning).
Complete US scanning of the pancreas was per-
formed. The ductal and parenchymal features (Fig. 1)
were recorded on a standardized form. The visibility of
pancreatic head, body and tail was graded from 1 to 4
(1 5 good, 2 5 adequate, 3 5 poor, 4 5 not visible).
The data were acquired from the segments of the pancreas
with the best visualization.Rosemont score
The weighted Rosemont score for EUS-detected
features of CP comprises five parenchymal and five
ductal features (Catalano et al. 2009). These features
with definitions and weighting are described in Table 3.
We applied the definitions and weighting unchanged
from the Rosemont consensus on the detected transabdo-
minal US features.of chronic pancreatitis. (a) Ultrasound image of several
creas. (b) Ultrasound image revealing a large, shadowing
ted duct in pancreatic body (right arrow). (c) Ultrasound
he main pancreatic duct in the body of the pancreas.
Table 3. Parenchymal and ductal features of chronic pancreatitis in the Rosemont criteria
Rank Definition Major Minor
Parenchymal features
1. Hyper-echoic foci with shadowing Echogenic structures.2 mm in length and width that produce a shadow; at
least 3 are needed to be a marker of CP
Major A
2. Lobularity
A. Without honeycombing Well circumscribed .5-mm structures with rims hyper-echoic relative to




B. With honeycombing When at least 3 of the lobules are contiguous, the feature is termed
honeycombing
3. Hyper-echoic foci without shadowing Echogenic structures .2 mm in length/width; no shadow Yes
4. Cysts Anechoic, rounded/elliptic structures .2 mm in short axis Yes
5. Stranding Hyper-echoic lines.3 mm, seen in at least 2 image planes; at least 3 strands
necessary; should be evaluated in body and tail and ventral pancreas
Yes
Ductal features
1. MPD calculi Echogenic structures with acoustic shadowing within MPD; can be
considered in all segments
Major A
2. Irregular MPD contour A main duct that is uneven and ectatic in its course; should be assessed only
from the pancreatic body and tail
Yes
3. Dilated side branches Presence of 3 or more tubular anechoic structures eachmeasuring.1mm in
width, communicating with the MPD; assessed only from the pancreatic
body and tail
Yes
4. MPD dilation MPD diameter .3.5 mm within the pancreatic head/body or .1.5 mm
within the tail (no consensus)
Yes
5. Hyperechoic MPD margin A relatively hyper-echoic duct wall found in.50% of the entire MPD in the
body and tail; when imaged in a parallel or perpendicular orientation,
both proximal and distal MPD borders must be hyper-echoic
Yes
Rosemont score for parenchymal and ductal features of chronic pancreatitis
I. Consistent with CP A. 1 major A feature 1 $3 minor features
B. 1 major A feature 1 1 major B feature
C. 2 major A features
II. Suggestive of CP A. 1 major A feature 1 ,3 minor features
B. 1 major B feature 1 $3 minor features
C. $5 minor features (any)
III. Indeterminate for CP A. 3 to 4 minor features, no major features
B. Major B feature alone or with 3 minor features
IV. Normal #2 minor features, no major features
CP 5 chronic pancreatitis, MPD 5 main pancreatic duct.
Source: Modified from Catalano et al. (2009).
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The classic EUS assessment of sonographic features
in CP is performed by counting the features detected in
each patient. Traditionally, a cutoff of three to five fea-
tures has been considered for the diagnosis of CP
(Catalano et al. 1998; Iglesias-Garcia et al. 2015; Sahai
et al. 1998; Stevens et al. 2010; Wiersema et al. 1993).
We also performed an unweighted counting of the US-
detected features. In our study, we chose to use three fea-
tures as the cutoff for calculation of accuracy. Others have
described the registration of nine EUS features (Stevens
et al. 2010). For simplicity, we chose to use all 10 Rose-
mont EUS features as the basis for the counting.Exocrine function testing
Pancreatic exocrine function was evaluated using a
timed, secretin-stimulated endoscopic short test
described elsewhere (Erchinger et al. 2013; Tjora et al.2013). Patients were offered conscious sedation with
intravenous midazolam during the test procedure. The
peak bicarbonate concentration was measured; the
cutoff for exocrine failure was defined as ,80 mmol/L
(Conwell et al. 2003; Erchinger et al. 2013; Stevens
et al. 2008).
Fecal elastase 1 was analyzed with a commercial
monoclonal analysis kit (ScheBo Biotech, Giessen, Ger-
many). A fecal elastase 1 level,200 mg/mg was consid-
ered pathologic (Loser et al. 1996). Patients with both
tests under threshold were considered exocrine insuffi-
cient according to the Mayo score.Statistical analysis
Statistics were calculated using SPSS Version 22
(IBM, Armonk, NY, USA) and SigmaPlot 11 (Systat
Software, San Jose, CA, USA). Normal distribution of
the samples was tested with the Kolmogorov–Smirnov
Transabdominal US in chronic pancreatitis d T. ENGJOM et al. 739test. Results are given as the median (95% confidence in-
terval [CI] or interquartile [IQ] range). Comparisons be-
tween groups were made using Student’s t-test or the
Mann–Whitney U-test as appropriate. The level of statis-
tical significance was set at 5%. Accuracy was calculated
from receiver operating characteristic (ROC) curves.
Inter-rater agreement for the detection of calcifications
and cysts by US compared with CTwas calculated as Co-
hen’s k. Agreement was defined according to Landis and
Koch (1977): 0 5 no agreement, 0 – 0.20 5 slight agree-
ment, 0.21–0.40 5 fair agreement, 0.41–
0.60 5 moderate agreement, 0.61–0.80 5 substantial
agreement and 0.81–15 almost perfect agreement. Clin-
ically relevant agreement usually requires a value .0.5
(Altman 1997).Fig. 2. Flowchart of patient enrollment. CP 5 chronic pancre-
atitis, US 5 ultrasound.Ethics
The study was conducted in accordance with the
Helsinki Declaration (World Medical Association
General Assembly 2015) and received institutional re-
view board approval from the Regional Committee for
Ethics in Medical and Biologic Research, Western Nor-
way (REK–Vest, Registration No. 2010/2857-7). The
study is registered as a clinical trial: ClinicalTrials.gov
Identifier: NCT01059669. All patients signed an
informed consent. The protocol adheres to the STARD
statement (Bossuyt et al. 2015).RESULTS
Participants
Patient enrollment was conducted during the period
January 2011 to June 2016. One hundred forty-one
eligible patients were evaluated. Seven patients did not
fulfill the protocol for an adequate Mayo score and
were not included. Ten patients (7%) who had insufficient
US visualization of the pancreas were excluded. A few
patients were included despite missing values for one of
the exocrine tests or missing demographics.
Accordingly, we included 124 patients with
acceptable-quality US. Patient inclusion and exclusion
are displayed in Figure 2. CP was diagnosed in 54 pa-
tients with a Mayo score$4. Seventy patients with vary-
ing diagnoses (recurrent acute pancreatitis, functional
dyspepsia, bile stone disease or other cause of abdominal
pain) were assigned a Mayo score ,4. These patients
were included as a control group. The Rosemont score
from US categorized the patients into four groups: (I)
consistent with CP (n 5 31), (II) suggestive of CP
(n 5 14), (III) indeterminate for CP (n 5 10) and (IV)
normal pancreas (n 5 69). The CP patients had lower
body mass indexes and higher median HbA1c values; a
larger percentage of CP patients was smokers and had
reduced exocrine pancreatic function compared with thenon-CP group. Median alcohol intake at the time of inclu-
sion was lower in the CP than in the non-CP group. There
were no differences between the groups with respect to
age or sex. Other than some discomfort accompanying
the endoscopic examinations, no adverse events were re-
ported during any of the examination procedures.
Visualization
Of the 134 total eligible patients who fulfilled the
Mayo score, the whole pancreas could be visualized in
82 patients (61%) (visualization score #2 in all 3 seg-
ments), and sufficient visualization for inclusion was
achieved in 124 patients (92%). The pancreatic tail was
the part of the pancreas most frequently incompletely
visualized (34 patients, 25%). In 10 patients, visualiza-
tion of the entire pancreas was inadequate to determine
a US score.
Visualization of calcifications and cysts by US
We calculated inter-rater agreement between US and
CT for calcifications and cysts. The calculation was per-
formed on the subgroup of 111 patients for whom CT
scans were available. US and CT detection of calcifica-
tions were in almost perfect agreement (k5 0.91). Agree-
ment between US detection and CT detection of cysts was
substantial (g 5 0.69).
Diagnostic accuracy of transabdominal US
We calculated ROC curves for the two US scoring
methods (Rosemont and classic scores) against the
740 Ultrasound in Medicine and Biology Volume 43, Number 4, 2017diagnosis CP by Mayo score (Fig. 3). Cutoffs for the
sonographic diagnosis were defined as a classic score of
$3 and Rosemont categories I and II. Both scoring sys-
tems yielded very high accuracies of $0.95 (Table 4).
There was somewhat better sensitivity and specificity
for US in the Rosemont score compared with the classic
score for the suggested cutoffs, but the difference be-
tween the areas under the ROC curves did not reach sta-
tistical significance (Fig. 3). We performed a subanalysis
on the group with minimal change CP represented by
Mayo scores 0–6 (n 5 90). In this group we calculated
a sensitivity of 0.55 (0.32–0.77) and a specificity of
0.99 (0.92–1) for the Rosemont score.Rosemont US category and exocrine function
When we divided the patients into groups with
prominent US changes (US Rosemont categories I and
II) and less prominent US changes (US Rosemont cate-
gories III and IV), we found that the groups with the
most prominent changes also had the most severe
exocrine failure (p , 0.001) and the highest prevalence
of exocrine failure (p , 0.001) (Fig. 4).DISCUSSION
To our knowledge, this is the only prospective clin-
ical report evaluating the use of transabdominal US
compared with a relevant diagnostic standard for CP dur-
ing the last 20 y.We applied two different scoring systemsFig. 3. Receiver operating characteristic curve of diagnostic ac-
curacy of the Rosemont and classic scores of transabdominal ul-
trasound (US) features. Variances for the area under the curve
(A) are listed in Table 4.developed for EUS to the pancreatic US findings in a pop-
ulation of well-characterized patients. Our study had
three main findings: First, we found that pancreatic US
has good diagnostic accuracy for diagnosing CP in both
scoring systems. We also found that disease severity rep-
resented by grade of exocrine failure was correlated to
severity of sonographic changes in the CP group. The
agreement between transabdominal US and CT in the
detection of calcifications and cysts was excellent.
Knowledge of the diagnostic performance of trans-
abdominal US in CP is based on old studies (Bolondi
et al. 1989; Foley et al. 1980; Gebel et al. 1985; Ikeda
et al. 1994). The German clinical practice guideline for
CP (Mayerle et al. 2013) describes the specificity of US
as good (70%–97%), whereas the method has pitfalls
with respect to sensitivity (60%–81%). Reports evalu-
ating transabdominal US of the pancreas in CP after the
substantial improvement in US and imaging technology
during the last two decades have been requested
(Conwell et al. 2014). Our results confirm that dedicated
transabdominal US of the pancreas has good specificity
under adequate scanning conditions and that the overall
accuracy has improved compared with most of the exist-
ing studies. The advantage of the Rosemont score over
the traditional counting of EUS features has not been
determined in EUS (Del et al. 2012; Kalmin et al. 2011;
Stevens et al. 2010). We found that by applying the
principles from the Rosemont consensus to
transabdominal US findings we achieved better
sensitivity for our suggested cutoffs, but the accuracy
did not significantly differ. The most reliable and major
features in the Rosemont score detected by US are
calcifications. This feature is scored with the highest
weight in the Rosemont score, whereas some minor
features have poorer detection rate with US and are
consequently weighted lower.
This study adds to our knowledge on the overall
diagnostic accuracy of US features in CP, with use of a
modern US scanner, and explores the advantage of
weighted scores in the evaluation of findings obtained
with this modality.
Methodologic considerations
The Rosemont score was developed to fit the perfor-
mance of EUS. The score is not validated for US. DirectTable 4. Accuracy of unweighted (classic) and
Rosemont scores for the diagnosis of chronic pancreatitis
US scores Sensitivity Specificity Cutoff Accuracy
Classical
score
0.69 (0.54–0.80)* 0.97 (0.90–1) $3 0.95 (0.91–0.99)
Rosemont
score
0.81 (0.69–0.91) 0.97 (0.90–1) #2 0.97 (0.93–1)
* Median (95% confidence interval).
Fig. 4. Boxplot of peak duodenal bicarbonate concentration of
secretin-stimulated duodenal juice for Rosemont ultrasound
groups I and II versus groups III and IV. Boxes represent me-
dians and quartiles. Error bars above and below the box indicate
the 90th and 10th percentiles, respectively. Dots indicate out-
liers outside the 90% confidence interval.
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frequencies and much longer sound wave distance to
examined structures may be difficult. The limitations in
inter-rater agreement for defined sonographic features
of CP described earlier for EUS may also be a limitation
for transabdominal US. The operators discussed and
agreed on general definitions of the individual features
before starting the study. We did not analyze inter-rater
agreement.
The detail in EUS is superior to that in most US ex-
aminations. The depth and probe frequency may interfere
with the interpretation of US features. However, under
perfect sonographic conditions in non-obese individuals
and with the additional use of transabdominal high-
frequency probes, wewere able to obtain high-quality im-
ages of the whole or a sufficient part of the pancreas. In
many cases we failed to obtain a complete US image of
the pancreas from body to tail. This may reduce sensi-
tivity in cases of focal disease. For some features, the fre-
quency of the transducer may play a role. Interface
echoes appear as the US traverses echo-rich structures
and layers. Ductal walls reflect a more prominent echo
at lower US frequency than at higher US frequency.
This may have implications for the interpretation of
ductal structures. Because of interface echo differences,
the cutoff values of EUS for main ductal dilation may
be inappropriate for US measures. However, in the pre-
sent study, we did not alter this definition. We strictly
applied the ‘‘leading edge to leading edge’’ measurementprinciple (Erchinger et al. 2011) to minimize the effect of
transducer frequency variation.
For visualization of calcifications and cysts with un-
specified location, we found that US performed well
compared with CT. On the other hand, differentiation be-
tween intra- and extra-ductal locations of the calcifica-
tions and the detection of minor features such as
stranding, minor duct dilations and duct wall hyper-
echogenicity are challenging in US. We postulate that
because of the higher spatial resolution of EUS, the detec-
tion of these weaker features is more relevant for the EUS
modality. This may explain why the weighted score, in
which major features are given a high weighting, per-
forms better on US.
Diagnostic standards for CP are challenging, and a
new definition has been proposed (Whitcomb et al.
2016). The old Cambridge criteria (Sarner and Cotton,
1984) are based on endoscopic retrograde cholangiopan-
creatography (ERCP) and, thus, not practically appli-
cable as a modern standard because ERCP is no longer
a frequently used diagnostic modality. The most wide-
spread standard is the M-ANNHEIM criteria (Schneider
et al. 2007). This comprehensive classification system
comprises several subsystems for diagnostic definition,
risk factor classification, disease staging and multimodal
image evaluation. For research, the system has drawbacks
in its complexity.
We chose to use the simple diagnostic MAYO score,
originally developed by Peter Layer (Layer et al. 1994).
This score combines imaging, histology, symptoms and
features of exocrine and endocrine failure in a simple nu-
merical score. The score was originally developed for
calcifying alcoholic pancreatitis, and is not validated in
all groups of CP. For both research and clinical purposes,
this score has the advantage of a clear numerical diag-
nostic definition. The score probably has limitations in
defining minimal-change CP.
Supplementary methods such as contrast-enhanced
ultrasonography and elastography have been developed
during the last decade. Small studies (Azemoto et al.
2015; Llamoza-Torres et al. 2016; Uchida et al. 2009;
Yashima et al. 2012) have evaluated the performance of
these modalities applied by external US in patients with
CP, but at present no clinical consensus regarding CP
has been arrived at with respect to these methods. The
evaluation of such modalities was outside the scope of
this study.
Study limitations
Studies on US and EUS are operator dependent. The
examinations were performed by operators blinded to
earlier history and radiologic imaging. Blinding to patient
appearance and communication during the procedurewas
not feasible. Blinding biases may exist.
742 Ultrasound in Medicine and Biology Volume 43, Number 4, 2017Patients with poor sonographic imaging of the
pancreas were excluded. Exclusions caused by obesity
or bowel gas may introduce a selection bias.
In characterization of the patients, different image
modalities (CT, MRI, EUS) were chosen as the best clin-
ical approach in the diagnostic workup process. The use
of different modalities may introduce variations in classi-
fications. We argue that this reflects a realistic image of
practical CP diagnostics.
The direct application of unadjusted EUS scoring
systems may not be completely feasible for the US-
detected features. To our knowledge, there are no valida-
tion studies on transcutaneous US using the Rosemont
score.
CONCLUSIONS
We have reported a clinically relevant evaluation of
the accuracy of transabdominal US of the pancreas using
modern US technology. We found that the modality has
good diagnostic accuracy and that the extent of sono-
graphic changes is reflected by the grade of exocrine fail-
ure. Someminor features were difficult to visualize by the
transabdominal approach. Adjustment of weighted scores
to fit the performance of transabdominal US in practical
CP diagnostics should be explored in future studies.
Our results support the place of US as a simple,
radiation-free and non-invasive first-line modality in the
clinical workup of patients with CP.
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